Wesser Research

"Where science and the marketplace meet"

Wesser Research clients are companies that are at the cutting edge of change management in a rapidly shifting healthcare environment. We play a role in helping them enhance internal capabilities and expand the scope of skill sets that they may not currently possess.

Our set of services are geared to help the large and mid-size pharmaceutical companies enhance current efforts in marketing and strategic planning and to provide marketing and planning services to smaller biotech companies that other consulting firms would view as too small to work on.

Finally, we believe that the work, while vital to both parties success, is important it is the RELATIONSHIP over time that sets us apart from other firms. We partner with your company over time, rather than view the relationship as an individual project-by-project effort. We work WITH you as much as work FOR you.

Market Research

Competitive Intelligence

Pharmaceutical Consulting

Sales Force Assessment and Effectiveness Studies

Strategic Planning Initiatives

New Blog...

8-9-11 Biogen and Abbott report positive results for new MS drug Biogen Idec (NASDAQ:BIIB – News) and Abbott (NYSE:ABT – News) today announced positive top-line results from SELECT, a global, registrational Phase 2b clinical trial designed to evaluate the investigational compound daclizumab high-yield process (DAC HYP) in people with relapsing-remitting multiple sclerosis (RRMS) over one year. Click here for the full story.

7-26-11 FDA rejects new use for JNJ's Simponi -- anssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response letter for its supplemental Biologics License Application (sBLA) for SIMPONI® (golimumab)... Click here for the full story.

7-7-11 Research Cuts May haunt Pfizer -- Pfizer Inc (PFE.N) may have won over shareholders with its recent decision to pare back research and development spending but could be shortchanging them in the long run, according to its former research chief.... Click here for the full story.

6-23-11 Cholesterol drugs in high doses lead to potential for developing diabetes -- People who take high doses of cholesterol-lowering drugs such asPfizer Inc. (PFE)'s Lipitor and AstraZeneca Plc (AZN)'s Crestor have a greater risk of developing diabetes and a lower risk of heart complications than those who take smaller amounts of the medicines, researchers said. Click here for the full story.

6-16-11 Pfizer may defeat Teva Patent challenge on Viagra -- The conventional thinking on Wall Street has been that Pfizer Inc.'s blockbuster anti-impotence pill Viagra will begin facing competition from cheaper generic knockoffs in the U.S. once its basic patent expires in 2012. Click here for the full story.